ARCA Biopharma CEO Richard B. Brewer: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Brewer speaks with the DAILY about ARCA’s product, a genetically targeted Phase III beta blocker abandoned by Bristol-Myers Squibb.
You may also be interested in...
ARCA Filing For Bucindolol Could Bring First Genetically Targeted CV Therapy
FDA has accepted an NDA for Gencaro (bucindolol), which could be the first cardiovascular drug approved with an accompanying pharmacogenomic test, ARCA Biopharma said Sept. 23
ARCA Filing For Bucindolol Could Bring First Genetically Targeted CV Therapy
FDA has accepted an NDA for Gencaro (bucindolol), which could be the first cardiovascular drug approved with an accompanying pharmacogenomic test, ARCA Biopharma said Sept. 23
ARCA Files NDA For Bucindolol; First Genetically Targeted CV Therapy?
ARCA biopharma and LabCorp partnered in companion genetic test for the beta blocker.